Table 1. Demographic and Laboratory Findings Among Parkinson’s Disease Patients and Controls.
| Parkinson’s disease (N = 61) | Controls (N = 135) | P value | |
|---|---|---|---|
| Sex, male, n (%) | 34 (55.73) | 68 (50.37) | 0.486 |
| Age, years | 68.90 ± 6.95 | 66.78 ± 6.51 | 0.040 |
| Co-morbidities | |||
| Hypertension, n (%) | 25 (40.98) | 2 (1.48) | < 0.001 |
| Diabetes, n (%) | 4 (6.56) | 0 | 0.009 |
| CAD, n (%) | 3 (4.92) | 1 (0.74) | 0.090 |
| Dyslipidemia, n (%) | 14 (22.95) | 2 (1.48) | < 0.001 |
| BMI (kg/m2) | 21.52 ± 3.94 | 21.06 ± 3.22 | 0.388 |
| Disease duration (years) | 5.62 ± 4.19 | - | - |
| H&Y stage, n (%) | - | - | |
| H&Y I | 13 (21.31) | ||
| H&Y II | 23 (37.70) | ||
| H&Y III | 11 (18.03) | ||
| H&Y IV | 11 (18.03) | ||
| H&Y V | 3 (4.92) | ||
| UPDRS score | |||
| All | 72.82 ± 47.31 | 2.04 ± 2.57 | < 0.001 |
| Non-motor (part I + II) | 27.85 ± 19.36 | 1.35 ± 2.11 | < 0.001 |
| Motor (part III) | 39.52 ± 26.68 | 0.69 ± 1.10 | < 0.001 |
| Motor (part IV) | 5.44 ± 6.58 | 0 ± 0 | < 0.001 |
| Hemoglobin, g/L | 124.23 ± 11.74 | 123.74 ± 15.01 | 0.806 |
| SCr, µmol/L | 74.63 ± 17.73 | 71.72 ± 13.76 | 0.257 |
| SUA, µmol/L | 304.22 ± 82.55 | 324.28 ± 77.66 | 0.102 |
| SUA/SCr ratio | 4.12 ± 0.90 | 4.59 ± 1.04 | 0.003 |
| Albumin, g/L | 41.75 ± 3.16 | 45.20 ± 32.58 | 0.076 |
| AST, IU/L | 25.13 ± 15.46 | 23.36 ± 7.70 | 0.853 |
| ALT, IU/L | 16.80 ± 15.62 | 18.00 ± 11.52 | 0.039 |
| Total bilirubin, µmol/L | 7.92 ± 3.67 | 6.59 ± 2.78 | 0.003 |
| Direct bilirubin, µmol/L | 3.39 ± 1.45 | 3.33 ± 1.16 | 0.592 |
| Indirect bilirubin, µmol/L | 4.52 ± 2.48 | 3.26 ± 1.82 | < 0.001 |
Data are expressed as mean ± SD unless indicated otherwise. BMI: body mass index; CAD: coronary artery disease; H&Y: Hoehn-Yahr; UPDRS: unified Parkinson’s disease rating scale; SUA: serum uric acid; SCr: serum creatinine; SUA/SCr: serum uric acid/serum creatinine; AST: aspartate aminotransferase; ALT: alanine aminotransferase.